October 10, 2018 / 9:19 PM / 2 months ago

BRIEF-Novartis Announces Data From Trial To Show Superior Efficacy Of Gilenya Over Copaxone In Patients With Relapsing Remitting Multiple Sclerosis

Oct 10 (Reuters) - Novartis AG:

* NOVARTIS ANNOUNCES NEW DATA FROM THE FIRST DIRECT HEAD-TO-HEAD TRIAL TO DEMONSTRATE SUPERIOR EFFICACY OF GILENYA® OVER COPAXONE® IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

* SAYS DATA SHOW THAT GILENYA 0.5MG MET ITS PRIMARY ENDPOINT OF SIGNIFICANTLY REDUCING ANNUALIZED RELAPSE RATE COMPARED TO COPAXONE

* SAFETY OF GILENYA OBSERVED IN ASSESS ACROSS BOTH DOSES WAS CONSISTENT WITH KNOWN SAFETY PROFILE OF DRUG Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below